Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177671 · ClinicalTrials.gov registry record · Phase 4
Antidepressant Medication Plus Donepezil for Treating Late-life Depression
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
NCT00177671: Completed Phase 4 study, sponsored by University of Pittsburgh.
NCT00177671 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 220 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177671, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
Primary Outcome
Cognitive performance was assessed with 17 well established and validated individual tests measuring multiple domains. We transformed raw scores for individual tests into Z-scores using the baseline distribution of a non-depressed, cognitively normal, older adult comparison group (N=36)of similar age, education, and medical health recruited concurrently with the depressed participants. These Z-scores were averaged within each neuropsychological area to produce domain scores and then averaged ove
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG Escitalopram
- DRUG Donepezil
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2003-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
What the finished NCT00177671 record still lists
NCT00177671 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00177671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00177671 about?
NCT00177671 is a clinical study titled "Antidepressant Medication Plus Donepezil for Treating Late-life Depression". This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals w...
What is the current status of trial NCT00177671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2003-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00177671?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), Escitalopram (DRUG), Donepezil (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00177671?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00177671's enrollment target sits among peer trials
220 385th of 2000 higher than 1,612 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia